The Business Research Company’s report on the Berinert Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
Which emerging drivers are set to accelerate the growth of the berinert market further?
The rise in the prevalence of genetic disorders is expected to propel the berinert market going forward. A genetic disorder is a health condition caused by abnormalities in an individual’s DNA, which can result from mutations in single or multiple genes, chromosomal changes, or a combination of genetic and environmental factors. Genetic disorders are rising due to factors such as increased environmental exposures, advancements in genetic testing, changes in reproductive patterns, heightened awareness and diagnosis, and the impact of lifestyle factors. Berinert is used to treat hereditary angioedema (HAE), a genetic disorder, by providing a C1 esterase inhibitor to prevent and manage acute swelling episodes. For instance, in April 2023, according to The United States National Library of Medicine, a US-based medical library, the total genetic tests carried out in the US in 2021 accounted for 35,000, which reached 37,271 tests in 2022. Therefore, the rise in the prevalence of genetic disorders drives the berinert market.
Access Your Free Sample of the Global Berinert Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=19995&type=smp
What are the key factors influencing the forecasted market size of the berinert industry?
The berinert market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to strong clinical evidence supporting efficacy, government funding, insurance support, strategic partnerships, and increasing spending.
The berinert market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to evolving guidelines, increased research and development, market expansion, strong physician advocacy, and growth in genetic research. Major trends in the forecast period include prophylactic treatments, home-based treatment, expansion in emerging markets, development of new inhibitors, and focus on non-IV treatment.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=19995&type=smp
Who are the leading competitors in the berinert market?
Major companies operating in the berinert market include CSL Behring
Which emerging trends are set to transform the berinert market landscape?
The key trend in the berinert market is focusing on advancements in treatment, such as the twice-weekly subcutaneous injection formulation of Berinert 60 IU/kg that can be self-administered at home to gain a competitive edge in the industry. It is a lyophilized human C1-esterase inhibitor concentrate that can be easily reconstituted and injected subcutaneously by the patient. For instance, in September 2022, CSL Behring K.K., a Japan-based biotechnology company, received manufacturing and marketing approval for Berinert S.C. Injection 2000 from the Ministry of Health, Labour and Welfare in Japan. This approval was supported by the COMPACT study, which found that acute hereditary angioedema (HAE) attacks were significantly lower in the Berinert 60 IU/kg group, with an average of 0.52 attacks per month compared to 4.03 attacks per month in the placebo group (p < 0.001, mixed model).
How do different geographies compare in terms of market share and growth potential in the berinert market?
North America was the largest region in the berinert market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the berinert market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/berinert-global-market-report
Which major segments of the berinert market are experiencing the fastest growth?
The berinert market covered in this report is segmented –
1) By Indication: Hereditary Angioedema (HAE), Acquired Angioedema (AAE)
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End Users: Adult, Geriatric, Pediatric
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19995
How is the berinert market defined?
Berinert is a prescription medication containing C1 esterase inhibitor (human), a protein derived from human plasma. It is primarily used to treat hereditary angioedema (HAE), a rare genetic disorder characterized by episodes of severe swelling in various body parts, such as the face, hands, feet, abdomen, or airway. Berinert replaces the deficient or malfunctioning C1 esterase inhibitor protein in HAE patients. This protein helps regulate the complement and contact systems, which are involved in inflammation and blood vessel permeability.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
